Related references
Note: Only part of the references are listed.Hepatotoxicity induced by antituberculosis drugs among patients coinfected with HIV and tuberculosis
Maria de Fátima Silva de Lima et al.
Cadernos de Saude Publica (2012)
Incidence, Clinical Features and Impact on Anti-Tuberculosis Treatment of Anti-Tuberculosis Drug Induced Liver Injury (ATLI) in China
Penghui Shang et al.
PLOS ONE (2011)
Pharmacogenetic & Pharmacokinetic Biomarker for Efavirenz Based ARV and Rifampicin Based Anti-TB Drug Induced Liver Injury in TB-HIV Infected Patients
Getnet Yimer et al.
PLOS ONE (2011)
HIV care and treatment factors associated with improved survival during TB treatment in Thailand: an observational study
Jay K. Varma et al.
BMC INFECTIOUS DISEASES (2009)
Adverse events to antituberculosis therapy: influence of HIV and antiretroviral drugs
D. J. B. Marks et al.
INTERNATIONAL JOURNAL OF STD & AIDS (2009)
A prospective study of antituberculous drug-induced hepatotoxicity in an area endemic for liver diseases
Hoda A. Makhlouf et al.
HEPATOLOGY INTERNATIONAL (2008)
Antituberculosis drug-induced hepatotoxicity: Concise up-to-date review
Alma Tostmann et al.
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY (2008)
Anti-Tuberculosis Therapy-Induced Hepatotoxicity among Ethiopian HIV-Positive and Negative Patients
Getnet Yimer et al.
PLOS ONE (2008)
Adverse reactions of anti tuberculosis drugs in hospitalized patients: incidence, severity and risk factors
Mohammad Reza Javadi et al.
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY (2007)
Complications of antiretroviral therapy in patients with tuberculosis: Drug interactions, toxicity, and immune reconstitution inflammatory syndrome
Helen McIlleron et al.
JOURNAL OF INFECTIOUS DISEASES (2007)
Antiretroviral therapy-induced liver alterations
Ulrich A. Walker
CURRENT OPINION IN HIV AND AIDS (2007)
Efavirenz 600 mg/day versus efavirenz 800 mg/day in HIV-infected patients with tuberculosis receiving rifampicin: 48 weeks results
W Manosuthi et al.
AIDS (2006)
Issues in the management of HIV-related tuberculosis
WJ Burman
CLINICS IN CHEST MEDICINE (2005)
Evaluation of patient-related factors associated with causality, preventability, predictability and severity of hepatotoxicity during antituberclosis treatment
M Sharifzadeh et al.
PHARMACOLOGICAL RESEARCH (2005)
Incidence of hepatotoxicity due to antitubercular medicines and assessment of risk factors
R Shakya et al.
ANNALS OF PHARMACOTHERAPY (2004)
Medical progress: Drug-induced hepatotoxicity
WM Lee
NEW ENGLAND JOURNAL OF MEDICINE (2003)
Evaluation of clinical and immunogenetic risk factors for the development of hepatotoxicity during antituberculosis treatment
SK Sharma et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2002)
Share Paper
